51results about "Proteoglycans" patented technology

Disclosed are new recombinant isoforms of human-like lubricin or PRG4 glycoprotein having outstanding lubrication properties and a novel glycosylation pattern, and methods for their manufacture at high levels enabling commercial production.

This new chimeric antigen receptor (CAR) T-cell therapy effectively treats cancer while minimizing the risk of dangerous inflammatory responses such as cytokine release syndrome. [Solution] An isolated nucleic acid sequence encoding a CAR, wherein the CAR includes an antigen-binding domain specific to glypican 3 (GPC3), the antigen-binding domain has an equilibrium dissociation constant (KD) of approximately 100 nanomoles (nM) or less, and the CAR construct provides an isolated nucleic acid sequence that does not induce cytokine production in GPC3-expressing cells.

A mesoangioblast composition is disclosed, in which the mesoangioblasts (MABs) are engineered to express a truncated agrin protein.

In the field of biological therapy, a major hurdle is the need for a platform technology that enables high bioavailability and long therapeutic exposure of a biological therapy in the setting of localized disease. Classical approaches result in problematic trade-offs such as toxicity and off-target side effects. The present disclosure provides compounds comprising follistatin domain 1 (FSD1) of follistatin (FST) which are able to bind biological structures, such as the extracellular matrix, through heparan sulfates, without bearing the undesirable neutralizing effects on activin A, myostatin, and GDF11 activities of e.g. full-length follistatin. The invention relates to fusion proteins or conjugated proteins, and compositions thereof, constructs or vectors encoding thereof, medical uses thereof and methods for biological therapy.

A protein polymer and a production process therefor. The protein polymer is obtained by means of stimulating MSCs, lysing same, and separating and purifying same. The protein polymer has a strong capability to repair oxidative damage, and thus can reduce the range of cerebral infarction, improve neural functions, inhibit the level of neuroinflammation, and increase the number of surviving neurons.

Provided are a use of recombinant calreticulin in hair growth, hair breeding, hair protection or anti-hair loss and a related product. The recombinant protein is derived from the full length of calreticulin or a fragment thereof, and has the functions of treating hair loss and improving hair by means of injection or application. Therefore, calreticulin is expected to be developed into an effective method and means for treating hair loss and improving hair.

The disclosure provides Myxoma virus that expresses one or more immunomodulatory transgenes and its use in inhibiting and / or treating a hematological cancer in a subject. The disclosure also provides a leukocyte having a Myxoma virus that expresses one or more immunomodulatory transgenes and the use of the leukocyte for inhibiting and / or treating a hematological cancer in a subject.

Engineered T cells are provided that express (a) a chimeric antigen receptor wherein the antigen binding domain of the CAR binds to human GPC3 (“a GPC-CAR”); and (b) an orthogonal receptor. Also provided are methods of making and using such engineered T cells.

To provide a method for producing proteoglycan that can produce proteoglycan in a simpler manner than conventional methods for producing proteoglycan and can produce proteoglycan in which a core protein is bound to a sugar chain.SOLUTION: The method for producing proteoglycan disclosed herein includes an extraction step of extracting an extract containing proteoglycan from an animal tissue, the proteoglycan containing a core protein and a glycan, and the core protein and the glycan being bound to each other.SELECTED DRAWING: Figure 4

Provided is an application of a protein polymer in the preparation of a drug for treating autism. Research has found that protein polymers derived from mesenchymal stem cells stimulated under stress conditions, such as ultraviolet irradiation, have a certain therapeutic effect on autism, providing a possibility for the treatment of autism.

The present disclosure provides an agent capable of reducing endotoxin and used for reducing endotoxin in animal tissue-derived proteoglycan, and a method for producing proteoglycan and capable of reducing endotoxin. The agent of the present disclosure for reducing endotoxin in the animal tissue-derived proteoglycan comprises a nonionic surfactant.

The present invention provides a simple, low-cost method for producing highly pure proteoglycan from a crushed cartilage tissue, a squeezed product of the crushed cartilage tissue, or an extract of the crushed or squeezed product. The crushed cartilage tissue, the squeezed product of the crushed cartilage tissue, or an extract of the crushed or squeezed product is immersed in or added to an aqueous solution containing salt, and alcohol is added to the resulting liquid composition in an amount to give a final concentration of 10 to 60% by volume to precipitate proteoglycans; alternatively, the crushed cartilage tissue, the squeezed product of the crushed cartilage tissue, or an extract of the crushed or squeezed product is immersed in or added to an aqueous solution containing salt and alcohol in an amount to give a final concentration of 10 to 60% by volume to precipitate proteoglycans.

The present invention relates to the use of MayDay peptide fragments designated decorin 31-170, decorin 31-188, decorin 31-177, decorin 31-169, or decorin 1-188 (the N-terminal fragment of the decorin protein) in the treatment and prevention of soft tissue inflammation and related disorders such as inflammatory bowel disease, Crohn's disease, ulcerative colitis, osteoarthritis, anal fistula, and lupus. Methods of modulating tissue repair and modulating stem cell mobilization are also contemplated in the present invention.

The present invention is directed to the use of MayDay peptide fragments, named Decorin31-170, Decorin31-188, Decorin31-177, Decorin31-169 or Decorinl-188 (Decorin protein N-terminal fragments) in the treatment and prevention of tissue ischemia and diseases associated with ischemia such as myocardial infarction (MI), reperfusion injury, organ transplantation, wound healing, stroke, cardiomyopathy and heart failure. Also anticipated in the present invention is methods of modulating tissue repair and modulating stem cell recruitment.

A protein polymer and a use thereof in the treatment of Alzheimer's disease. The protein polymer is obtained by stimulating MSCs, and then lysing the MSCs and performing separation and purification. The protein polymer has a strong oxidative damage repair ability, can improve Alzheimer's disease-related biomarker abnormalities, and has a significant treatment effect on Alzheimer's disease.

Provided are CAR-T compositions against GPC3, including chimeric receptors, and engineered immune cells against GPC3. The present disclosure also provides vectors, compositions, and methods of treatment using GPC3 antigen binding molecules and engineered immune cells. The GPC3 CAR compositions provided herein can be used to treat some cancers.

Provided are CAR-T compositions that are directed to GPC3, including chimeric receptors, and engineered immune cells to GPC3. The disclosure also provides vectors, compositions, and methods of treatment using GPC3 antigen binding molecules and engineered immune cells. GPC3 CAR compositions provided herein can be used for the treatment of certain cancers.

An Agrin peptide which induces proliferation of cardiomyocytes for treating a heart disease is provided.

The present disclosure provides an agent capable of reducing endotoxin and used for reducing endotoxin in animal tissue-derived proteoglycan, and a method for producing proteoglycan and capable of reducing endotoxin. The agent of the present disclosure for reducing endotoxin in the animal tissue-derived proteoglycan comprises a nonionic surfactant.

The present invention relates to homing peptide-directed decorin conjugates for the treatment of epidermolysis bullosa, and corresponding methods of treatment. The use of novel homing peptides enables the targeting of the conjugates in vivo to specifically home to the skin and skin wounds by systemic administration.

Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.

The presently claimed and described technology provides vaccine compositions comprising at least two mutant-calreticulin (CALR)-peptides, wherein the at least two peptides have overlapping sequences and methods for administration of the vaccine compositions to induce or elicit an antitumor response or improve or enhance antitumor T cell immunity and methods of preventing, treating, reducing, or slowing progression or development of a hematological malignancy in a subject with a calreticulin mutation.

Engineered T cells are provided that express (a) a chimeric antigen receptor wherein the antigen binding domain of the CAR binds to human GPC3 ("a GPC-CAR"); and (b) an orthogonal receptor. Also provided are methods of making and using such engineered T cells.

The present disclosure relates to compositions and methods for treating cancer using chimeric antigen receptor T cells that target glypican 3.

The present invention is directed to the use of MayDay peptide fragments, named Decorin31-170, Decorin31-188, Decorin31-177, Decorin 31-169 or Decorin 1-188 (Decorin protein N-terminal fragments) in the treament and prevention of soft tissue inflammation and associated diseases inflammatory bowel disease, Crohns disease, ulcerative colitis, osteoarthristis, fistulas and lupus. Also anticipated in the present invention is methods of modulating tissue repair and modulating stem cell recruitment.

The present disclosure produces proteoglycan in a simpler manner than known methods for producing proteoglycan, and provides a method capable of producing proteoglycan with a core protein and sugar chains bonded. The method for producing proteoglycan of the present disclosure includes: extracting an extract c proteoglycan from a tissue of an animal. The proteoglycan comprises a core protein and a sugar chain, and the core protein and the sugar chain are bonded.

Use of a protein polymer in the treatment of amyotrophic lateral sclerosis. The protein polymer is obtained by stimulating and subsequently lysing mesenchymal stem cells, followed by isolation and purification. In SOD1 mutant mouse experiments, the protein polymer can significantly increase the number of motor neurons in the spinal anterior horn, ameliorate muscle atrophy, improve the motor ability of mice, and prolong the survival time of mice. In clinical trials, the protein polymer exhibits the effect of blocking the progression of amyotrophic lateral sclerosis, can reduce the concentration of TDP-43 protein in cerebrospinal fluid, and can increase the concentration of TDP-43 protein in serum.

Provided herein are compositions, systems, kits, and methods for treating glial scarring caused by injury to a central nervous system (CNS) site by administering a CSPG reduction peptide (CRP), or a nucleic acid sequence encoding the CRP. In particular embodiments, CNS site is the result of a stroke in a subject (e.g., human subject that has had a stroke). In certain embodiments, the CRP is composed of a cell membrane penetrating domain, a lysosome targeting domain, and a chondroitin sulfate proteoglycan (CSPG) binding domain.

An Agrin peptide which induces proliferation of cardiomyocytes for treating a heart disease is provided.

The present invention is directed to the use of MayDay peptide fragments, named Decorin31-170, Decorin31-188, Decorin31-177, Decorin 31-169 or Decorin 1-188 (Decorin protein N-terminal fragments) in the treament and prevention of respiratory inflammation and associated diseased Acute Respiratory Distress (ARDS), Chronic Obstructive Pulmonary Disease (COPD), asthma, bronchitis and pulmonary fibrosis. Also anticipated in the present invention is methods of modulating tissue repair and modulating stem cell recruitment.